Tag
3 articles tagged AI Drug Discovery.
LeashBio leverages DNA-encoded libraries and rigorous data hygiene to generate high-quality training data for small molecule discovery. The company addresses the 'Clever Hans' problem in ML by prioritizing internal data over noisy public repositories, enabling robust generalization and novel chemical reasoning.
Zara Therapeutics executives detail how causal perturbation data, diffusion language models, and open-science strategies are restructuring biotech R&D. The analysis covers virtual cell commercialization, clinical trial de-risking, and the strategic shift from observational to predictive biological AI.
Genesis Molecular AI leaders discuss the strategic shift toward sub-angstrom precision, physics-informed synthetic data, and agentic workflows in drug discovery. The episode outlines how AI companies are commercializing through pharma partnerships, overcoming GPU bottlenecks, and redefining industry benchmarks for viable therapeutic development.
